XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$28.19 USD
-1.66 (-5.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.49 +0.30 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
XOMA Royalty Corporation [XOMA]
Reports for Purchase
Showing records 81 - 100 ( 332 total )
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials; We Look to Novartis Milestone Payments in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
1Q18 Results; Locked and Loaded; Now Awaiting First Transaction of New Business Model
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Right Sandbox, Right Time, Waiting for Right Buyer; IL-2 Antibody Program Primed, Ready, and Differentiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Strong Q4/FY17 Financials and Potential Licensing Revenues in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
FY2017 Results; Bring on the Deals; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
We Recommend Buying XOMA on Weakness Due to Intact Fundamentals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
2017 Was the Setup; 2018 Should Start Knockin''em Down; Target Increased to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Another Nice Early Feather in the Cap for XOMA''s New Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
CANTOS Data Continue to Impress; XOMA a Clear Beneficiary of Drug''s Likely Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
3Q17 Results; Leveraging the New Model Going Into 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Not Your Grandmother''s XOMA; Streamlined and Validated New Approach; Assuming Coverage at Buy and $38 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Another Milestone for Xoma2.0 and September 21 Management Access Call
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM; Ka-ching! IL-1beta Licenses Validate XOMA2.0
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L